Abstract:Macrocyclic peptides are predominantly peptide structures bearing one or more rings and spanning multiple amino acid residues. Macrocyclization has become a common approach for improving the pharmacological properties and bioactivity of peptides. A variety of ribosomal-derived and non-ribosomal synthesized cyclization approaches have been established. The biosynthesis of backbone macrocyclic peptides using seven new emerging methodologies will be discussed with regard to the features and strengths of each platform rather than medicinal chemistry tools. The mRNA display variant, known as the random nonstandard peptide integrated discovery (RaPID) platform, utilizes flexible in vitro translation (FIT) to access macrocyclic peptides containing nonproteinogenic amino acids (NAAs). As a new discovery approach, the ribosomally synthesized and post-translationally modified peptides (RiPPs) method involves the combination of ribosomal synthesis and the phage screening platform together with macrocyclization chemistries to generate libraries of macrocyclic peptides. Meanwhile, the split-intein circular ligation of peptides and proteins (SICLOPPS) approach relies on the in vivo production of macrocyclic peptides. In vitro and in vivo peptide library screening is discussed as an advanced strategy for cyclic peptide selection. Specifically, biosynthetic bicyclic peptides are highlighted as versatile and attractive modalities. Bicyclic peptides represent another type of promising therapeutics that allow for building blocks with a heterotrimeric conjugate to address intractable challenges and enable multimer complexes via linkers. Additionally, we discuss the cell-free chemoenzymatic synthesis of macrocyclic peptides with a non-ribosomal catalase known as the non-ribosomal synthetase (NRPS) and chemo-enzymatic approach, with recombinant thioesterase (TE) domains. Novel insights into the use of peptide library tools, activity-based two-hybrid screening, structure diversification, inclusion of NAAs, combinatorial libraries, expanding the toolbox for macrocyclic peptides, bicyclic peptides, chemoenzymatic strategies, and future perspectives are presented. This review highlights the broad spectrum of strategy classes, novel platforms, structure diversity, chemical space, and functionalities of macrocyclic peptides enabled by emerging biosynthetic platforms to achieve bioactivity and for therapeutic purposes.

Macrocyclic-Based Strategy in Drug Design: from Lab to the Clinic

Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals

Macrocycles and Macrocyclization in Anticancer Drug Discovery: Important Pieces of the Puzzle.

The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery

An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review

Discovery of Macrocyclic CDK2/4/6 Inhibitors with Improved Potency and DMPK Properties Through a Highly Efficient Macrocyclic Drug Design Platform

Biosynthetic Strategies for Macrocyclic Peptides

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Macrocyclic Compounds For Drug And Gene Delivery In Immune-Modulating Therapy

Macrocycle-Based Supramolecular Drug Delivery Systems: A Concise Review

Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery

Peptide/protein-based Macrocycles: from Biological Synthesis to Biomedical Applications

Recent Advances in Peptide Macrocyclization Strategies.

Recent Advances in Non‐Standard Macrocyclic Peptide Ligand Discovery using mRNA Display

Peptide Macrocycles Developed from Precisely Regulated Multiple Cyclization of Unprotected Peptides

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges

Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors

Large Libraries of Structurally Diverse Macrocycles Suitable for Membrane Permeation

Biocompatible Strategies for Peptide Macrocyclisation

Cyclopropyl Scaffold: A Generalist for Marketed Drugs

Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets